A Prehospital Acute Stroke Trial has Only Modest Impact on Enrollment in Concurrent, Post-arrival-Recruiting Stroke Trials.


Journal

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
ISSN: 1532-8511
Titre abrégé: J Stroke Cerebrovasc Dis
Pays: United States
ID NLM: 9111633

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 01 07 2020
revised: 20 07 2020
accepted: 22 07 2020
entrez: 17 10 2020
pubmed: 18 10 2020
medline: 24 11 2020
Statut: ppublish

Résumé

Because "time is brain," acute stroke trials are migrating to the prehospital setting. The impact upon enrollment in post-arrival trials of earlier recruitment in a prehospital trial requires delineation. We analyzed all patients recruited into acute and prevention stroke trials during an 8-year period when an academic medical center (AMC) was participating in a prehospital treatment trial - the NIH Field Administration of Stroke Treatment - Magnesium (FAST-MAG) study. During the study period, in addition to FAST-MAG, the AMC participated in 33 post-arrival stroke trials: 27 for acute cerebral ischemia, one for intracerebral hemorrhage, and 5 secondary prevention trials. Throughout the study period, the AMC was recruiting for at least 3 concurrent post-arrival acute trials. Among 199 patients enrolled in acute stroke trials, 98 (49%) were in FAST-MAG and 101 (51%) in concurrent, post-arrival acute trials. Among FAST-MAG patients, 67% were not eligible for any concurrent acute, post-arrival trial. Of 134 patients eligible for post-arrival acute trials, 101 (76%) were enrolled in post-arrival trials and 32 (24%) in FAST-MAG. Leading reasons FAST-MAG patients were ineligible for post-arrival acute trials were: NIHSS too low (23.4%), intracranial hemorrhage (17.9%), IV tPA used in standard management (9.0%), NIHSS too high (7.1%), and age too high (5.2%). A prehospital hyperacute stroke trial with wide entry criteria reduced only modestly, by one-fourth, enrollment into concurrently active, post-arrival stroke trials. Simultaneous performance of prehospital and post-arrival acute and secondary prevention stroke trials in research networks is feasible.

Sections du résumé

BACKGROUND BACKGROUND
Because "time is brain," acute stroke trials are migrating to the prehospital setting. The impact upon enrollment in post-arrival trials of earlier recruitment in a prehospital trial requires delineation.
METHODS METHODS
We analyzed all patients recruited into acute and prevention stroke trials during an 8-year period when an academic medical center (AMC) was participating in a prehospital treatment trial - the NIH Field Administration of Stroke Treatment - Magnesium (FAST-MAG) study.
RESULTS RESULTS
During the study period, in addition to FAST-MAG, the AMC participated in 33 post-arrival stroke trials: 27 for acute cerebral ischemia, one for intracerebral hemorrhage, and 5 secondary prevention trials. Throughout the study period, the AMC was recruiting for at least 3 concurrent post-arrival acute trials. Among 199 patients enrolled in acute stroke trials, 98 (49%) were in FAST-MAG and 101 (51%) in concurrent, post-arrival acute trials. Among FAST-MAG patients, 67% were not eligible for any concurrent acute, post-arrival trial. Of 134 patients eligible for post-arrival acute trials, 101 (76%) were enrolled in post-arrival trials and 32 (24%) in FAST-MAG. Leading reasons FAST-MAG patients were ineligible for post-arrival acute trials were: NIHSS too low (23.4%), intracranial hemorrhage (17.9%), IV tPA used in standard management (9.0%), NIHSS too high (7.1%), and age too high (5.2%).
CONCLUSIONS CONCLUSIONS
A prehospital hyperacute stroke trial with wide entry criteria reduced only modestly, by one-fourth, enrollment into concurrently active, post-arrival stroke trials. Simultaneous performance of prehospital and post-arrival acute and secondary prevention stroke trials in research networks is feasible.

Identifiants

pubmed: 33066919
pii: S1052-3057(20)30618-2
doi: 10.1016/j.jstrokecerebrovasdis.2020.105200
pmc: PMC7573197
mid: NIHMS1616979
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105200

Subventions

Organisme : NINDS NIH HHS
ID : U01 NS044364
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Références

Stroke. 2006 Jan;37(1):123-8
pubmed: 16322489
J Med Ethics. 2017 Dec;43(12):803-809
pubmed: 28108613
Clin Trials. 2010 Aug;7(4):312-21
pubmed: 20595245
Int J Stroke. 2014 Feb;9(2):220-5
pubmed: 24444117
Crit Care. 2013 Jan 08;17(1):R1
pubmed: 23298553
Stroke. 2004 May;35(5):e106-8
pubmed: 15017009
N Engl J Med. 2015 Feb 5;372(6):528-36
pubmed: 25651247
Int J Stroke. 2014 Feb;9(2):215-9
pubmed: 24444116
Stroke. 2014 Jan;45(1):159-67
pubmed: 24203849
Stroke. 2013 Nov;44(11):3120-8
pubmed: 24003041
Resuscitation. 2010 Jul;81(7):792-5
pubmed: 20418007
Cerebrovasc Dis. 1999 Nov-Dec;9(6):305-13
pubmed: 10545686
J Stroke Cerebrovasc Dis. 2012 Feb;21(2):131-42
pubmed: 20719541
Emerg Med J. 2014 Dec;31(12):994-9
pubmed: 24078198
Crit Care Med. 2009 Jan;37(1 Suppl):S107-11
pubmed: 19104209
J Natl Cancer Inst. 2015 Dec 29;108(2):
pubmed: 26714555
Stroke. 1995 Jul;26(7):1289-92
pubmed: 7604428
Stroke. 2016 Nov;47(11):2737-2741
pubmed: 27679533

Auteurs

Phoebe Johnson-Black (P)

Univ of Los Angeles, 710 Westwood Plaza, Los Angeles 90095, CA, United States. Electronic address: phoebejohnson@mednet.ucla.edu.

Gregory Wong (G)

University of Washington, St. Louis, MO, United States.

Sidney Starkman (S)

Univ of California, Los Angeles, Los Angeles, CA, United States.

Nerses Sanossian (N)

Univ of Southern California, Los Angeles, CA, United States.

Latisha Sharma (L)

Univ of California, Los Angeles, Los Angeles, CA, United States.

May Kim-Tenser (M)

Univ of California, Los Angeles, Los Angeles, CA, United States.

David Liebeskind (D)

Univ of California, Los Angeles, Los Angeles, CA, United States.

Lucas Restrepo-Jimenez (L)

Univ of California, Los Angeles, Los Angeles, CA, United States.

Miguel Valdes-Sueiras (M)

Univ of California, Los Angeles, Los Angeles, CA, United States.

Samuel Stratton (S)

Univ of California, Los Angeles, Los Angeles, CA, United States.

Marc Eckstein (M)

Univ of Southern California, Los Angeles, CA, United States.

Frank Pratt (F)

Univ of California, Los Angeles, Los Angeles, CA, United States.

Robin Conwit (R)

NINDS, Bethesda, MD, United States.

Scott Hamilton (S)

Stanford Univ, Palo Alto, CA, United States.

Judy Guzy (J)

Univ of California, Los Angeles, Los Angeles, CA, United States.

Ileana Grunberg (I)

Univ of California, Los Angeles, Los Angeles, CA, United States.

Kristina Shkirkova (K)

Univ of California, Los Angeles, Los Angeles, CA, United States.

Claude Hemphill (C)

Univ of California, San Francisco, San Francisco, CA, United States.

Jeffrey Saver (J)

Univ of California, Los Angeles, Los Angeles, CA, United States.
University of California, Department of Neurology, Los Angeles, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH